RE: 6103 advantages7 Apr 2026 19:12
JRDC ------"precision is easily the most exciting oncology advancement for decades imo. i just hope avacta don't **** it up for us investors who have supported them for years and are still massively down and flog it all on the cheap to american mates. i'll be raging if this goes for less than £5 a share."
I think you have neatly summed up what a few here may be feeling.
I have certainly seen that with other shares I have invested in as, no doubt, have others.
However, I think CC is above that, and am confident that her list of priorities would be along the lines of No 1 --the cancer patients, No 2 --the Shareholders who have financed this, and No 3 --the Avacta chemists for their excellent work.
I am not usually that confident with my opinions about others, but CC is an exception.